▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2169 by analyst upside · 2026-08-13
CI
The Cigna Group
Healthcare · Market Cap $73B · P/E 11.3x
ANALYST PRICE TARGET
+23.1%
implied upside to consensus target
Current Price $277.41
Consensus Target $341.42
Bull Target $400.0
Bear Target $290.0
Analysts Covering 24
ANALYST CONSENSUS - BUY
Strong Buy
6
Buy
13
Hold
5
Sell
0
52-Week Low $239.51
52-Week High $315.47
YTD Return +0.5%
FUNDAMENTALS
Market Cap $73B
P/E Ratio (TTM) 11.3x
Forward P/E 8.3x
EPS (TTM) $24.50
PEG Ratio 0.83
Dividend Yield 2.28%
Revenue (TTM) $282.4B
Profit Margin 2.3%
52-WEEK RANGE
52-Week Low $239.51
52-Week High $315.47
Current Price $277.41
Bear Target $290.0
Bull Target $400.0
● Now $277.41 ● Target $341.42
TRADING DATA
Avg Volume 1.7M
YTD Return +0.5%
Analyst Count 24
Consensus Buy
Upside to Target +23.1%
Last Updated 2026-08-13

ANALYST SUMMARY

The Cigna Group (CI) is currently trading at $277.41 with a Wall Street consensus price target of $341.42, implying potential upside of 23.1% over the next 12 months. 24 analysts currently cover CI, with a consensus rating of Buy - 79% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $400.0, while the most cautious has a target of $290.0.

CI operates in the Healthcare sector with a market capitalisation of $73B. The stock is up 0.5% year-to-date and is currently trading near the lower end of its 52-week range of $239.51 – $315.47.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

BSX +21.9%
Boston Scientific Corporation
$75B · P/E 20.8x · Buy
ELV +12.5%
Elevance Health, Inc.
$87B · P/E 17.3x · Buy
HCA +9.6%
HCA Healthcare, Inc.
$90B · P/E 13.8x · Buy
REGN +4.5%
Regeneron Pharmaceuticals, Inc.
$82B · P/E 19.7x · Buy
COR +18.6%
Cencora, Inc.
$60B · P/E 23.4x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CI, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Mizuho - Reiterated
Outperform → Outperform 2026-06-08 Building track record
Barclays ↓ Downgrade
Overweight → Equal-Weight 2026-05-26 Building track record
UBS - Reiterated
Buy → Buy 2026-05-22 33% win rate (6 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-05-20 Building track record
Deutsche Bank ↓ Downgrade
Buy → Hold 2026-05-20 Building track record
Bernstein - Reiterated
Outperform → Outperform 2026-05-05 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-05-04 62% win rate (8 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-05-01 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
61
out of 100
Coverage depth
25/30
Consensus clarity
22/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →